Oligonucleotides conjugated to short lysine chains

Bioconjugate Chemistry

Volumn 16, Issue 4, 2005, Pages 1038-1044

  Winkler, Johannes ^a   Urban, Ernst ^a   Noe, Christian R ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; DICHROISM; ESTERS; MASS SPECTROMETRY; NANOCATALYSTS; PEPTIDES; SYNTHESIS (CHEMICAL);

BENZYL ESTERS; CARBOXYL GROUPS; CYCLOHEXADIENES; HYDROGEN DONOR; PALLADIUM NANOPARTICLES; PEPTIDE SYNTHESIS; PHASE-TRANSFER REACTION; PHOSPHOROTHIOATE OLIGONUCLEOTIDE; SOLID PHASE SYNTHESIS; ]+ CATALYST;

OLIGONUCLEOTIDES;

COMPLEMENTARY DNA; LYSINE; NANOPARTICLE; OBLIMERSEN; OLIGONUCLEOTIDE; OLIGONUCLEOTIDE PHOSPHOROTHIOATE; PROTEIN BCL 2; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CHEMICAL STRUCTURE; CIRCULAR DICHROISM; DRUG CONJUGATION; DRUG TARGETING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; PEPTIDE SYNTHESIS; SYNTHESIS;

EID: 22644446801     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc049729d     Document Type: Article

References (64)

1. Zamecnik, P. C., and Stephenson, M. L. (1978) Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc. Natl. Acad. Sci. U.S.A. 75, 280-284.
2. Crooke, S. T. (2000) Potential roles of antisense technology in cancer chemotherapy. Oncogene 19, 6651-6659.
3. Crooke, S. T. (1999) Molecular mechanisms of action of antisense drugs. Biochim. Biophys. Acta 1489, 31-44.
4. Urban, E., and Noe, C. R. (2003) Structural modifications of antisense oligonucleotides. Farmaco. 58, 243-258.
5. Freier, S. M., and Altmann, K. H. (1997) The ups and downs of nucleic acid duplex stability: structure-stability studies on chemically modified DNA: RNA duplexes. Nucleic Acids Res. 25, 4429-4443.
6. Levin, A. A. (1999) A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. Biochim. Biophys. Acta 1489, 69-84.
7. Orr, R. M. (2001) Technology evaluation: fomivirsen, Isis Pharmaceuticals Inc/CIBA vision. Curr. Opin. Mol. Ther. 3, 288-294.
8. Tamm, I., Dorken, B., and Hartmann, G. (2001) Antisense therapy in oncology: new hope for an old idea? Lancet 358, 489-497.
9. Bayes, M., Rabasseda, X., and Prous, J. R. (2004) Gateways to clinical trials. Methods FindExp Clin Pharmacol. 26, 473-503.
10. Frantz, S. (2004) Lessons learnt from Genasense's failure. Nat Rev Drug Discovery 3, 542-543.
11. Klasa, R. J., Gillum, A. M., Klem, R. E., and Frankel, S. R. (2002) Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment. Antisense Nucleic Acid Drug Dev. 12, 193-213.
12. Adams, J. M., and Cory, S. (1998) The Bcl-2 protein family: arbiters of cell survival. Science. 281, 1322-1326.
13. Jansen, B., Wacheck, V., Heere-Ress, E., Schlagbauer-Wald, H., Hoeller, C., Lucas, T., Hoermann, M., Hollenstein, U., WoIff, K., and Pehamberger, H. (2000) Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet 356, 1728-1733.
14. Wacheck, V., Krepier, C., Strommer, S., Heere-Ress, E., Klem, R., Pehamberger, H., Eichler, H. G., and Jansen, B. (2002) Antitumor effect of G3139 Bcl-2 antisense oligonucleotide is independent of its immune stimulation by CpG motifs in SCID mice. Antisense Nucleic Acid Drug Dev. 12, 359-367.
15. Dias, N., and Stein, C. A. (2002) Potential roles of antisense oligonucleotides in cancer therapy. The example of Bcl-2 antisense oligonucleotides. Eur. J. Pharm. Biopharm. 54, 263-269.
16. Raffo, A., Lai, J. C., Stein, C. A., Miller, P., Scaringe, S., Khvorova, A., and Benimetskaya, L. (2004) Antisense RNA down-regulation of bcl-2 expression in DU145 prostate cancer cells does not diminish the cytostatic effects of G3139 (Oblimersen). Clin Cancer Res. 10, 3195-3206.
17. Lai, J. C., Benimetskaya, L., Santella, R. M., Wang, Q., Miller, P. S., and Stein, C. A. (2003) G3139 (oblimersen) may inhibit prostate cancer cell growth in a partially bis-CpG-dependent non-antisense manner. Mol Cancer Ther. 2, 1031-1043.
18. Manoharan, M. (1999) 2′-carbohydrate modifications in antisense oligonucleotide therapy: importance of conformation, configuration and conjugation. Biochim. Biophys. Acta 1489, 117-130.
19. Wagner, E., Oberhauser, B., Holzner, A., Brunar, H., Issakides, G., Schaffner, G., Gotten, M., Knollmueller, M., and Noe, C. R. (1991) A simple procedure for the preparation of protected 2′-O-methyl- or 2′-O-ethylribonucLeoside 3′O-phosphoramidites. Nucleic Acids Res. 19, 5965-5971.
20. Gotten, M., Oberhauser, B., Brunar, H., Holzner, A., Issakides, G., Noe, C. R., Schaffner, G., Wagner, E., and Birnstiel, M. L. (1991) 2′-O-methyl, 2′-O-ethyl oligoribonucleotides and phosphorothioate oligodeoxyribonucleotides as inhibitors of the in vitro UT snRNP-dependent mRNA processing event. Nucleic Acids Res. 19, 2629-2635.
21. Werner, D., Brunar, H., and Noe, C. R. (1998) Investigations on the influence of 2′-O-alkyl modifications on the base pairing properties of oligonucleotides. Pharm. Acta Helv. 73, 3-10.
22. Lima, W. F., and Crooke, S. T. (1997) Binding affinity and specificity of Escherichia coli RNase H1: impact on the kinetics of catalysis of antisense oligonucleotide-RNA hybrids. Biochemistry. 36, 390-398.
23. Monia, B. P., Lesnik, E. A., Gonzalez, C., Lima, W. F., McGee, D., Guinosso, C. J., Kawasaki, A. M., Cook, P. D., and Freier, S. M. (1993) Evaluation of 2′-modified oligonucleotides containing 2′-deoxy gaps as antisense inhibitors of gene expression. J. Biol. Chem. 268, 14514-14522.
24. Manoharan, M., Prakash, T. P., Barber-Peortt, I., Bhat, B., Vasquez, G., Ross, B. S., and Cook P. D. (1999) N-(Z-Cyanoethoxycarbonyloxy)succinimide: A New Reagent for Protection of Amino Groups in Oligoriucleotides. J. Org. Chem. 64, 6468-6472.
25. Summerton, J. (1999) Morpholino antisense oligomers: the case for an RNase H-independent structural type. Biochim. Biophys. Acta 1489, 141-158.
26. Braasch, D. A., and Corey, D. R. (2001) Locked nucleic acid (LNA): fine-tuning the recognition of DNA and RNA. Chem. Biol. 8, 1-7.
27. Braasch, D. A, Liu, Y., and Corey, D. R. (2002) Antisense inhibition of gene expression in cells, by oligonucleotides incorporating locked nucleic acids: effect of mRNA target sequence and chimera design. Nucleic Acids Res. 30, 5160-5167.
28. Tung, C.-H., and Stein, S. (2000) Preparation and Applications of Peptide-Oligonucleotide Conjugates, Bioconjugate Chem. 11, 605-618.
29. Letsinger, R. L., and Chaturvedi, S. (1998) Tailored hydrophobic cavities in oligonucleotide-steroid conjugates. Bioconjugate Chem. 9, 826-830.
30. Shea, R. G., Marsters, J. C., and Bischofberger, N. (1990) Synthesis, hybridization properties and antiviral activity of lipid-oligodeoxynucleotide conjugates. Nucleic Acids Res. 18, 3777-3783.
31. Stein, S., and Zhu, T. (1997) Preparation of vitamin B6-peptide and vitamin B6-peptide-oligonucleotide conjugates. Methods Enzymol. 280, 51-58.
32. Maier, M. A., Yannopoulos, C. G., Mohamed, N., Roland, A., Fritz, H., Mohan, V., Just, G., and Manoharan, M. (2003) Synthesis of antisense oligonucleotides conjugated to a multivalent carbohydrate cluster for cellular targeting. Bioconjugate Chem. 14, 18-29.
33. Derossi, D., Chassaing, G., and Prochiantz, A. (1998) Trojan peptides: the penetratin system for intracellular delivery. Trends Cell Biol. 8, 84-87.
34. Pardridge, W. M., Boado, R. J., and Kang, Y.-S. (1995) Vector-mediated delivery of a polyamide (\"peptide\") nucleic acid analog through the blood-brain barrier in vivo. Proc. Natl. Acad. Sci. USA. 92, 5592-5596.
35. Branden, L. J., Mohamed, A. J., and Smith, C. I. E. (1999) A peptide nucleic acid-nuclear localization signal fusion that mediates nuclear transport of DNA. Nat. Biotechnol. 17, 784-787.
36. Benimetskaya, L., Guzzo-Pernell, N., Liu, S. T., Lai, J. C., Miller, P., and Stein, C. A. (2002) Protamine-fragment peptides fused to an SV40 nuclear localization signal deliver oligonucleotides that produce antisense effects in prostate and bladder carcinoma cells. Bioconjugate Chem. 13, 177-187.
37. Astriab-Fisher, A., Sergueev, D., Fisher, M., Shaw, B. R., and Juliano, R. L. (2002) Conjugates of Antisense Oligonucleotides with the Tat and Antennapedia Cell-Penetrating Peptides: Effects on Cellular Uptake, Binding to Target Sequences, and Biologic Actions. Pharm. Res. 19, 744-754.
38. Fisher, A. A., Ye, D., Sergueev, D. S., Fisher, M. H., Shaw, B. R., and Juliano, R. L. (2002) Evaluating the specificity of antisense oligonucleotide conjugates. A DNA array analysis. J. Biol. Chem. 277, 22980-22984.
39. Leonetti, J. P., Degols, G., and Lebleu, B. (1990) Biological activity of oligonucleotide-poly(L-lysine) conjugates: mechanism of cell uptake. Bioconjugate Chem. 1, 149-153.
40. Degols, G., Leonetti, J. P., Benkirane, M., Devaux, C., and Lebleu, B. (1992) Poly(L-lysine)-conjugated oligonucleotides promote sequence-specific inhibition of acute HIV-1 infection. Antisense Res. Dev. 2, 293-301.
41. Clarenc, J. P., Degols, G., Leonetti, J. P., Milhaud, P., and Lebleu, B. (1993) Delivery of antisense oligonucleotides by poly(L-lysine) conjugation and liposome encapsulation. Anti-Cancer Drug Des. 8, 81-94.
42. Ginobbi, P., Geiser, T. A., Ombres, D., and Citro, G. (1997) Folic acid-polylysine carrier improves efficacy of c-myc antisense oligodeoxynucleotides on human melanoma (M14) cells. Anticancer Res. 17, 29-35.
43. Sazani, P., Rang, S. H., Maier, M. A., Wei, C., Dillman, J., Summerton, J., Manoharan, M., and Kole, R. (2001) Nuclear antisense effects of neutral, anionic and cationic oligonucleotide analogs. Nucleic Acids Res. 29, 3965-3974.
44. Eritja, R., Pons, A., Escarceller, M., Giralt, E., and Albericio, F. (1991) Synthesis of defined peptide-oligonucleotide hybrids containing a nuclear transport signal sequence. Tetrahedron 47, 4113-4120.
45. Bongartz, J. P., Aubertin, A. M., Milhaud, P. G., and Lebleu, B. (1994) Improved biological activity of antisense oligonucleotides conjugated to a fusogenic peptide. Nucleic Acids Res. 22, 4681-4688.
46. Corey, D. R., Munoz-Medellin, D., and Huang, A. (1995) Strand invasion by oligonucleotide-nuclease conjugates. Bioconjugate Chem. 6, 93-100.
47. Haralambidis, J., Chai, M., and Tregear, G. W. (1987) Preparation of base-modified nucleosides suitable for non-radioactive label attachment and their incorporation into synthetic oligodeoxyribonucleotides. Nucleic Acids Res. 15, 4857-4876.
48. Zaramella, S., Yeheskiely, E., and Stromberg, R. (2004) A method for solid-phase synthesis of oligonucleotide 5́-peptide-conjugates using acid-labile alpha-amino protections. J. Am. Chem. Soc. 126, 14029-14035.
49. Manoharan, M., Tivel, K. L., and Cook, P. D. (1995) Lipidic nucleic acids. Tetrahedron Lett. 36, 3651-3654.
50. Manoharan, M., Inamati, G., Tivel, K. L., Conklin, B., Ross, B. S., and Cook, P. D. (1997) 2′- and 3′-cholesterol-conjugated adenosine and cytosine nucleoside building blocks: synthesis of lipidic nucleic acids. Nucleosides Nucleotides 16, 1141-1143.
51. Hwang, J.-T., and Greenberg, M. M. (2001) Synthesis of 2′-Modified Oligodeoxynucleotides via On-Column Conjugation. J. Org. Chem. 66, 363-369.
52. Kachalova, A., Zubin, E., Stetsenko, D., Gait, M., and Oretskaya, T. (2004) Oligonucleotides with 2′-O-carboxymethyl group: synthesis and 2′-conjugation via amide bond formation on solid phase. Org. Biomol. Chem. 2, 2793-2797.
53. Winkler, J., Urban, E., Losert, D., Wacheck, V., Pehamberger, H., and Noe, C. R. (2004) A novel concept for ligand attachment to oligonucleotides via a 2′-succinyl linker. Nucleic Acids Res. 32, 710-718.
54. Vu, H., and Hirschbein, B. L. (1991) Internucleotide phosphite sulfurization with tetraethylthiuram disulfide. Phosphorothioate oligonucleotide synthesis via phosphoramidite chemistry. Tetrahedron Lett. 32, 3005-3008.
55. Pieles, U., Zurcher, W., Schar, M., and Moser, H. E. (1993) Matrix-assisted laser desorption ionization time-of-flight mass spectrometry: a powerful tool for the mass and sequence analysis of natural and modified oligonucleotides. Nucleic Acids Res. 21, 3191-3196.
56. Gilbert, M. (1999) Optimierung von Antisense-Oligonukleotiden - zwitterionische Nukleinsäuren und Trägersystem-variationen, Shaker Verlag, Aachen, Germany.
57. Griffey, R. H., Monia, B. P., Cummins, L. L., Freier, S., Greig, M. J., Guinosso, C. J., Lesnik, E., Manalili, S. M., Mohan, V., Owens, S., Ross, B. R., Sasmor, H., Wancewicz, E., Weiler, K, Wheeler, P. D., and Cook, P. D. (1996) 2′-O-aminopropyl ribonucleotides: a zwitterionic modification that enhances the exonuclease resistance and biological activity of antisense oligonucleotides. J. Med. Chem. 39, 5100-5109.
58. Soukchareun, S., Tregear, G. W., and Haralambidis, J. (1995) Preparation and characterization of antisense oligonucleotide-peptide hybrids containing viral fusion peptides. Bioconjugate Chem. 6, 43-53.
59. de La Torre, B. G., Albericio, F., Saison-Behmoaras, E., Bachi, A., and Eritja, R. (1999) Synthesis and binding properties of oligonucleotides carrying nuclear localization sequences. Bioconjugate Chem. 10, 1005-1012.
60. Henkel, B., Zhang, L., and Bayer, E. (1997) Investigations on solid-phase peptide synthesis in N-to-C direction (inverse synthesis). Liebigs Annalen / Recueil. 2161-2168.
61. Gutheil, W. G., and Xu, Q. (2002) N-to-C solid-phase peptide and peptide trifluoromethylketone synthesis using amino acid tert-butyl esters. Chem. Pharm. Bull. 50, 688-691.
62. Zaramella, S., Yeheskiely, E., and Stromberg, R. (2004) A method for solid-phase synthesis of oligonucleotide 5′-peptide-conjugates using acid-labile alpha-ammo protections. J. Am. Chem. Soc. 126, 14029-14035.
63. Clark, C. L., Cecil, P. K, Singh, D., and Gray, D. M. (1997) CD, absorption and thermodynamic analysis of repeating dinucleotide DNA, RNA and hybrid duplexes [d/r(AC)]12.[d/r(GT/U)] 12 and the influence of phosphorothioate substitution. Nucleic Acids Res. 25, 4098-4105.
64. Greenfield, N. J., and Fasman, G. D. (1969) Computed circular dichroism spectra for the evaluation of protein conformation. Biochemistry. 8, 4108-4116.